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The injectable progestogen only
contraceptive is a widely accepted method of
contraception in our environment and very little has
been reported on its complications in our
environment. The aim of the study was to highlight
the complications associated with use of Injectable
Medroxyprogesterone Acetate and Norethisterone
Enanthate in clients at the University of Port-
Harcourt Teaching Hospital, Port-Harcourt, South-
South Nigeria
It was a - 5 year retrospective study of the
clients who accepted and used progestogen only
i n j e c t a b l e c o n t r a c e p t i v e s ( d e p o t
medroxyprogesterone acetate and noerthistherone
enantate) at the family planning units of the
University of Port Harcourt Teaching Hospital
between 1st January 2000 and 31st December
2004. The case files of these clients were retrieved
their data extracted. The information included the
clients sociodemographic characteristics, the types
doses of of injectable contraceptives received and
the side effects reported at the follow up visits. The
data was coded and entered into a data bank and
analysed using SPSS for windows 11.0 version.
Seven hundred and seventy seven (777)
injectable contraceptive acceptors out of the 1720
contraceptive acceptors during the study period.
This accounted for 45.17% of the new acceptors
over the 5 years period, making the injectable
contraceptives the most commonly used method of
birth control in UPTH. Five hundred and five (505)
clients took depot medroxyprogesterone acetate
(DMPA) while 272 used norethesterone enanthate
(NE-ET). The mean age of the injectable
contraceptive users was 31.31±5.5 years and the
mean parity was 5.5±2.5 deliveries. The users
reported multiple side effects with 579 episodes.
Secondary amenorrhea was the commonest side
effect occurring in 350 (45.34%) clients. Others were
hypertension in 17 (2.94%) and metabolic
disturbances in 14 (2.41%).
Conclusion:
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Injectable progestogen only
contraceptive is associated with multiple side
effects, with secondary amenorrhoea being the
most common. The contraceptive failure rate of
this method in our women is low.
progestogen injectable contraceptive,
medroxyprogesterone acetate, norethisterone
e n a n t h a t e , c o m p l i c a t i o n s , s e c o n d a r y
amenorrhoea.
Introduction
From a global perspective, many countries
currently face the crises of a rapid growth of
human population that has begun to threaten
human survival. To stem this, the voluntary
control of fertility therefore became of
paramount importance to the modern society.
About 50% of all couples in the world are now
using a modern method of contraception.
Though the contribution of these contraceptives
to the betterment of health and life in general has
been simply tremendous, none of these including
the injectable progestins is without side effects/
complications.
These steroids acting primarily by inhibition of
ovulation, thickening of cervical mucus or
induction of endometrial atrophy, extensive
clinical experience accumulated over recent years
indicate that the available progestin-only
formulations: depo-medroxyprogesterone
acetate and norethisterone enanthate are highly
effective, long lasting and reversible agent of
fertility control, used by over 10million persons
globally.
However the use of some of these agents is not
without adverse effects and complications which
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resulting high discontinuation rates in some
studies .
Major concerns have also been raised over the long
term safety of these agents including the possibility
of induction of carcinogenesis, adverse metabolic
effects, cardiovascular diseases and osteoporosis.
But interestingly and contrary to the fears
expressed, no studies to date have demonstrated
increased incidence of any type of cancers,
ischaemic heart disease or cerebrovascular
accidents. Notable complications are
menstrual disorders including secondary
amenorrhea with its strong negative socio-cultural
perception in our environment , irregular vaginal
b l e e d i n g , m e n o r r h a g i a a n d
metrorrhagia. Other reported complications
include accidental pregnancies, weight changes,
decreased libido, abdominal and chest pains. Less
reported side effects are psychological and vaso
motor disturbances .
Port Harcourt, the Rivers state capital has been the
nerve center for oil and gas prospecting and refining
activities in Nigeria for over 50 years. The UPTH
draws its patients from a cross section of multi
ethnic and indigenous population who reside in
Port Harcourt and from its extended catchement
areas that traverse the difficult terrain of the Niger
Delta areas of Nigeria.
This was a – 5 retrospective study between 1st
January 2000 and 31st December 2004 evaluating
the complications of the two forms of progestogen
only injectable contraceptives (noerthisterone
enanthate and medroxyprogesterone acetate) in
clients at the family planning clinic of the University
of Port Harcourt Teaching Hospital. The case notes
of all the 777 clients who accepted and used
injectable medroxyprogesterone acetate and
norethisterone enanthate within this period were
identified and analyzed. The information extracted
were clients' age, parity, educational status, type
and doses of injections received, number of
discontinuations, side effects and complications.
The data was coded and entered into a data bank
and analyzed using SPSS for windows 11.0 version
and presented as frequency tables, means
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standard deviations, median values and
percentages.
After counselling by family planning nurse
practitioners and physicians, a full medical
history was taken and clinical examination
performed. Those who were pregnant or had
contraindications to progestogen hormonal
contraception were excluded.
A dose of 200mg norethisterone enanthate (NET-
EN) or 150mg medroxyprogesterone acetate
(MPA) was injected into the gluteal /deltoid
muscle within the first seven days of a normal
menstrual period where menstrual dates were
known. It was also given after abortion and six
weeks after delivery in breastfeeding mothers
who were yet to resume menstruation. Repeat
injections and observation were done after every
60 days for those receiving NET-EN and every 90
days for clients on MPA. At each visit, all the
complaints volunteered by the patient were
documented. The weight, blood pressure and
result of urinalysis were recorded. A patient was
considered lost to follow up if she defaulted more
than twice from scheduled injections.
The proportion of women reporting secondary
amenorrhea of two months or more during the
use of injectable contraceptives by number of
injections received was calculated. The values
obtained represent the conditional probabilities
of developing secondary amenorrhea after a
given number of two or three monthly injections
received. Woman-months of contraceptive
protection was calculated as the product of two
or three and the total number of injections
received, and the Pearl index, a measure of
contraceptive effectiveness was calculated with
the formula:
Pearl Index = Ax 100/B/12
Where A is the number of accidental pregnancies
during the use of the injectable contraceptives
and B is the number of woman-months of
contraceptive protection.
During the five year period under review, there
were 1720 new contraceptive acceptors. A total
of 777 (45.17%) of the acceptors used
progestogen only injectatable contraceptive.
Results
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Of these, 505 c l ients accepted depot
medroxyprogesterone acetate, while 272 clients
accepted norethisterone enanthate. This confirms
progestogen only injectable contraceptive as the
most accepted method of family planning in our
centre. Over 38.22% of the clients used it for
'permanent' contraception in place of sterilization,
while 58.81% used it for child spacing. The rest
were undecided as to the size of family they wanted
but still used it for contraception.
The age range of the clients was
17-43 years, with a mean ±SD of 31.31 ±5.5 years.
Seventy-five (0.96%) of the
clients did not have formal education, 167 (21.49%)
had primary education while 535 (68.85%) had
secondary to post secondary education as shown in
table II.
Table III shows the parity distribution of
clients. The parity ranged between 0-11 deliveries
with a mean parity ± SD parity of 5.5± 2.5 deliveries.
Five (0.6%) clients were nulliparous women, while
226 (29.1%) clients were grand multiparous
women.
Table IV shows the
distribution of doses of injection received. The
number of injections received by clients ranged
from one to twenty- three. Only four clients
received 20 doses of the injections and above,
corresponding to 168 woman-months. Two
hundred and eleven (27.15%) did not return for a
second injection, either because they discontinued
voluntarily, lost to follow up or were not yet due.
Two hundred and fifty four (32.69%) discontinued
after 2 to 4 injections. One hundred and eighty one




Dose of injection received:
At the
end of the study period 177 clients had received
at least two doses of the injections and were still
attending the clinic, excluding those who had just
received one injection and were not yet due for a
subsequent dose (30 clients). Discontinuations
were common (600), giving a cumulative
discontinuation rate of 77.22%.
The most common complications
were menstrual disorders occurring in
510(65.64%) of the clients. Secondary
amenorrhea was the commonest menstrual
disturbance reported in 60.05% of the study
population. The conditional probabilities of
developing secondary amenorrhea increased
with the doses of injections received, 27% at the
1st dose and 86% at the 9th dose.
The other menstrual disturbances encountered
in the study were menorrhagia (3.12%), irregular
menstruation (2.25%) and metrorrhagia and
intermenstrual bleeding occurred in 22.23%.
Seventeen (17) clients had blood pressure
elevation/ hypertension accounting for 2.95% of
the complications. They were subsequently
referred to the physicians and discontinued the
injections. Two (0.35%) had diabetes mellitus and
were also referred to the physicians and
discontinued. Injection abscess occurred in two
(0.35%) subjects.
Two (2) accidental pregnancies occurred, giving a
Pearl pregnancy index of 0.26 per woman years.
Miscellaneous disorders include chest/ joint pain
reported in 4 (0.69%) clients, mastodynia in
another 4 (0.69%), and abdominal/waist pain in 5
(0.86%) subjects as shown in table VI.
Complications :
Seventy three (9.34%) received 10 -19 while 4
clients received 20 injections and above.
Table I. Yearly distribution of clients receiving progestogen only injectable contraceptives
Year DMPA NET-EN Total Percentage
2000 100 82 182 23.4%
2001 89 49 138 17.8%
2002 139 21 160 20.6%
2003 106 50 156 20.1%
2004 71 70 141 18.1%
Grand total 505 272 777 100%
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Table II: Educational status
Level of education DMPA NET-EN Total Percentage
none 61 14 75 9.7%
Primary 125 42 167 21.4%
Secondary/tertiary 319 216 535 68.9%
Grand total 505 272 777 100.%
Table III. Parity distribution
Parity DMPA NET-EN Total Percentage
0 2 3 5 0.6%
1-4 329 217 546 70.3%
5-9 168 52 220 28.3%
=10 6 0 6 0.8%
Grand total 505 272 777 100%
Table IV. Distribution of doses of injection received
Dose DMPA NET-EN Total
1 131 80 211
2-4 148 105 253
5-9 118 63 181
10-14 0 14 14
15-19 54 19 73
20 0 4 4
Grand total 451 285 736
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Table V: Conditional probabilities of developing secondary amenorrhea
No. of injections No. of clients Clients with secondary
amenorrhea




1 113 30 0.265
2 91 40 0.439
3 82 49 0.597
4 47 31 0.659
5 42 32 0.769
6 28 22 0.786
7 20 16 0.80
8 23 19 0.826
9 16 14 0.875
10 17 15 0.882
11 8 7 0.875
12 14 13 0.920
=13 21 20 0.950
Table VI. Complications of injectable contraceptives






Irregular periods 13 2.25
Hypertension 17 2.95
Diabetes 2 0.35
Injection abscess 2 0.35
Weight gain 10 1.73
Weight loss 2 0.35
Headache 10 1.73
Palpitation 5 0.86
Decreased libido 4 0.69
Dizziness 2 0.35
Accidental pregnancy 2 0.35
Chest/joint pain 4 0.69
Mastodynia 4 0.69
Abdominal/waist pain 5 0.86
Total events 579 100
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Discussion
Menstrual disorders were the commonest
complications experienced by the study subjects,
occurring in 510 (65.64%) of the clients. This is in
keeping with results of previous studies. The
aetiology of this disturbance have been linked to
the endogenous ovarian steroid secretion.
Secondary amenorrhea was the most common
menstrual disturbance reported by over 60.05% of
the clients which was higher than the figure
reported in a previous Nigerian study , and
elsewhere . Also the conditional probabilities
o f d eve l o p i n g s e co n d a r y a m e n o r r h e a
corresponding to injections received were 0.27,
0.79, 0.86, also significantly higher than reported
in previous studies.
The comparatively higher rate of secondary
amenorrhea could be entirely due to chance in this
series. It could also be as a result of endometrial
atrophy or very rarely accidental pregnancy.
Two (2) accidental pregnancies occurred in this
series. The 0.05% discontinuation rate due to
secondary amenorrhea and the cumulative
discontinuation rate of 77.22% is inconsistent with
result of earlier findings elsewhere. Five
hundred and forty-five (70.14%) either
discontinued voluntarily or were lost to follow up.
Majority of clients in this group may have
discontinued voluntarily due to secondary
amenorrhea.
The other disturbances of menstruation
encountered in this study include menorrhagia
(3.12%), irregular vaginal bleeding (2.25%) and
metrorrhagia/intermenstrual bleeding in 22.23%.
Gulati etal14 reported irregular vaginal bleeding in
16% while Chaudhuri etal reported same in 57%
of their study subjects. These figures are relatively
higher than observed in this study. The reason for
this wide disparity is not exactly known, but
environmental factors may be partly responsible.
H o w e v e r, 3 . 1 2 % 0 f t h e c l i e n t s h a d
menorrhagia/prolonged bleeding. This is in
keeping with result of previous findings.
Inability to exclude clients with lactational
amenorrhea due to incomplete records and
defaults from scheduled injections by many
women affected the reported onset and pattern of











Two accidental pregnancies occurred, giving a
pearl index of 0.26 per woman years, comparable
to rates reported by other workers. The first
pregnancy occurred in September 2002 in a 29
year old lady after receiving eleven doses of depot
medroxyprogesterone acetate injections. The
second pregnancy occurred in September 2004 in
a 32 year old lady, para 2, after five doses of depo-
provera injections. Both pregnancies were
uneventful and carried to term. Outcomes were
live male babies with good Apgar scores and
average birth weights.
Although no ectopic pregnancies were observed
in this study, their occurrence have been reported
by other authors. Though not a desirable
outcome in this circumstance, it goes to reinforce
earlier observation by Gebbie etal, that
injectable contraceptive have no permanent
impact on fertility. This is particularly worrisome
when viewed against the backdrop that a good
proportion of women in our environment use
injectable contraceptives for terminal
contraception, due to fear and aversion to
surgical sterilization, even among women with
formal education. This was corroborated by the
finding in this study where 38.22% of the clients
accepted injectable contraceptives for terminal
contraception majority of this had formal
education.
The other major medical complication were
hypertension and diabetes mellitus observed in
2.95 and 0.35% of the clients respectively. Their
occurrence in previous studies have been
reported, but could be probably due to
apparent unmasking of pre-existing medical
condition which then got worse. Hypertension
had earlier been reported in 0.7% of acceptors of
hormonal implants in this center and a decrease
in glucose tolerance reported in studies
elsewhere. The19 clients with complicating
hypertension and diabetes mellitus in this series
subsequently discontinued with the injectables
and switched to intra uterine contraceptive
devices.
Injection abscess occurred in 2 of the clients. This
was lower than the figure reported following
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The other non-menstrual side effects include
weight related changes. One point seventy-three
(1.73%) of the study group reported increase in
their weight. These were confirmed with our
weighing scale. Weight gain is known to occur with
use of progestins . as they are anabolic and
tend to induce appetite. Normal age related
weight gain may have also been contributory in
these patients.
Two clients had significant weight loss
necessitating discontinuation. Similar weight loss
had been reported in this center and elsewhere,
though it could be due to other confounding factors
including nutritional and immunodeficiency states.
Vasomotor and psychological changes were also
reported by the subjects in this series. Another
1.73% had persistent headache, 0.86% had
palpitation, 0.69% had decreased libido while
0.35% reported dizziness. These disturbances have
also been reported by other authors. Other
miscellaneous disturbances reported elsewhere
and noted in less than 2% of the study group
include mastodynia, chest pain, abdominal pain,
waist pain and joint pain.
Other complications noted by previous authors but
not reported in this study include blurring of vision,
hot flushes, muscle cramps, acne, bloatedness,
decreased milk flow, varicose veins, astenia,
depression, urinary tract infection and
vulvovaginitis.
It has also been noted that short lasting reactions:
urge to cough, coughing fits, respiratory distress
occur in rare cases during or immediately after
injection of these drugs. These were not noted in
our patients. Possible long term consequencies
include risk of neoplasia, osteoporosis,
cerebrovascular accidents, thromboembolic
phenomenom, ischaemic heart disease and








It was not possible to identify these either
because the facilities were not available or they
require long term follow up which is particularly
difficult in our setting for obvious reasons, but it is
reassuring to note that parallel studies elsewhere
did not show any increased incidence of any type
of cancers, ischemic heart disease or
cerebrovascular accidents, and infact the
protective effect of these injectables against
endometrial carcinoma and uterine fibroids have
been reported.
In conclusion, since menstrual disorders remain
the major complications of progestogen only
injectable contraceptive and whereas a good
proportion of our contracepting women use them
for permanent contraception in preference to
surgical sterilization, adequate counselling at the
first visit about the possible menstrual
disturbances especially in the initial period, as
these tend to resolve or ameliorate later with
continued patronage. This is particularly
important when viewed against the backdrop
that the continued use of these agents depend on
their ability to accept and adapt to changes in
their menstrual pattern, and to tolerate other
side effects. Well informed and wholesome pre-
commencement counselling and re-enforcement
during follow up visit can do much to promote
satisfaction and hence continuous use of the
agents.
Alternatively, the one monthly combined
i n j e c t a b l e c o n t a i n i n g 2 5 m g
medroxyprogesterone acetate and 5mg of
estradiol cypionate per dose, with higher efficacy
and with bleeding pattern resembling those of
normal menstrual cycles, should be
introduced in our centers, since for many Nigerian
women of reproductive age, secondary
amenorrhea is erroneously thought to have
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